Treatment preferences and treatment satisfaction among psoriasis patients: a systematic review

Abstract

A critical gap exists in determining treatment preferences and treatment satisfaction from patient perspectives, which is paramount to achieving therapeutic success. The objective of this systematic review is to determine factors influencing treatment preferences and treatment satisfaction among psoriasis patients. PubMed, EMBASE, and Web of Science databases were searched between November 1, 2010, and December 1, 2017. Observational and interventional research studies published in the English language that discussed patient preferences and patient satisfaction in the treatment of psoriasis were reviewed and synthesized. We utilized data on treatment preferences and treatment satisfaction from 35,388 psoriasis patients based on 60 articles from the years 2010 to 2017. Treatment preferences were heterogeneous and changed over time among psoriasis patients. Across all treatment modalities, the most important treatment attributes were treatment location, probability of improvement, and delivery method. For biologics specifically, the most important attributes were risk of adverse events and probability of treatment benefit. Factors that influenced patients' preferences for certain treatments included age, sex, comorbidities, disease duration, and prior treatments. Notably, some psoriasis patients placed higher importance on a treatment's process attributes (e.g., access and delivery) over its outcome attributes (e.g., efficacy). Overall, patient satisfaction with existing therapies remains modest; however, those treated with biologic agents exhibited highest treatment satisfaction over oral therapy, phototherapy, and topical therapy.

Quality of life, treatment satisfaction, and adherence to treatment in patients with vesicular hand eczema: A cross‐sectional study

“…The “global satisfaction” was significantly higher for alitretinoin, ciclosporin, and dupilumab compared with nonsystemic treatments. In patients with psoriasis data also showed lower “global satisfaction” scores for patients receiving nonsystemic treatment . The use of biologicals for psoriasis resulted in substantially higher global patient satisfaction scores .…”

“…In patients with psoriasis data also showed lower "global satisfaction" scores for patients receiving nonsystemic treatment. 24,25 The use of biologicals for psoriasis resulted in substantially higher global patient satisfaction scores. 24,26 Recent observational studies showed promising results regarding the effectiveness of dupilumab in patients with hand eczema and might offer future perspectives for patients with difficult-to-treat vesicular hand eczema.…”

Female patients are less satisfied with biological treatment for psoriasis and experience more side‐effects than male patients: results from the prospective BioCAPTURE registry

“…For this purpose, the Treatment Satisfaction Questionnaire for Medication (TSQM) can provide insight into different domains of treatment satisfaction: effectiveness, convenience, global satisfaction and side‐effects . In general, treatment satisfaction with biologics is high, although we previously demonstrated that there still remains room for improvement in treatment satisfaction…”

Clinical Goals and Barriers to Effective Psoriasis Care

“…In previous surveys psoriasis patients have reported treatment dissatisfaction [ 2 ] and failure to meet treatment goals with current therapy [ 3 ]. A recent review of 60 published studies/articles, which included 35,388 psoriasis patients, noted modest patient satisfaction, with those patients treated with biologics reporting higher satisfaction than those treated with oral therapies, phototherapy, or topicals [ 8 ]. How these data would differ today given the introduction of the newer biologic therapies, such as interleukin (IL) inhibitors (IL-17 and IL-23), which have excellent clinical efficacy but significant cost issues, is yet to be determined.…”